Department of Pharmaceutics, Shivajirao.S. jondhale College of Pharmacy, Asangaon, Thane, Maharashtra
The Indian bulk drug, or Active Pharmaceutical Ingredient (API), industry forms the backbone of the nation’s pharmaceutical sector and is central to its role as the “pharmacy of the world.” This review examines the evolution, structure, and future trajectory of bulk drug production in India. Historically propelled by the Indian Patents Act (1970) and supported by strong chemical manufacturing capabilities, India has emerged as one of the largest global producers of APIs. However, dependence on imports of key starting materials (KSMs) from China poses strategic vulnerabilities. Recent policy measures—including the Production Linked Incentive (PLI) Scheme and the Bulk Drug Parks initiative—aim to restore self-reliance through investment incentives and infrastructure development. The paper also discusses regulatory frameworks governed by the CDSCO, technological advances such as continuous-flow chemistry and green synthesis, and environmental challenges in waste management and pollution control. Economic analyses reveal the industry’s significant contributions to GDP, employment, and export earnings. Looking forward, digitalisation, sustainable manufacturing, and R&D-driven innovation are expected to define the sector’s growth. Achieving API self-sufficiency and environmental sustainability will be crucial for India to strengthen its global leadership in pharmaceutical production.
India’s pharmaceutical sector has earned the global reputation of being the “pharmacy of the world,” supplying over 20% of global generic medicines and nearly 60% of global vaccine demand [1]. Within this vast industrial framework, bulk drug production—technically known as the manufacture of Active Pharmaceutical Ingredients (APIs)—forms the essential foundation of India’s pharmaceutical value chain. APIs are the biologically active components of drugs that generate therapeutic effects, and without a robust API ecosystem, formulation manufacturing becomes strategically vulnerable. India’s journey toward self-reliance in bulk drugs has been marked by innovation, policy shifts, and global integration.
The historical roots of India’s bulk drug sector can be traced to the early 20th century, when pioneering entrepreneurs such as Acharya P.C. Ray established Bengal Chemical and Pharmaceutical Works in 1901, followed by Alembic Chemical Works in 1907 [2]. These enterprises laid the groundwork for an indigenous chemical and drug manufacturing culture that later expanded rapidly after independence. Initially, India depended heavily on imported APIs, primarily from Western multinationals. The introduction of the Indian Patents Act (1970), which replaced product patents with process patents, revolutionised the landscape by allowing Indian firms to reverse-engineer patented molecules and develop cost-effective processes [3]. This single policy move catalysed the rise of domestic bulk drug manufacturers such as Cipla, Ranbaxy, Dr Reddy’s Laboratories, and Sun Pharma—firms that would later dominate both the API and formulation segments globally. The API industry underwent rapid expansion during the 1980s and 1990s, benefiting from a strong domestic chemical base, government investment in R&D institutions like the Council of Scientific and Industrial Research (CSIR), and the emergence of public-sector pharmaceutical giants such as Hindustan Antibiotics Limited (HAL) and Indian Drugs and Pharmaceuticals Limited (IDPL). By the mid-1990s, India had become self-sufficient in over 70% of its bulk drug requirements [4]. However, globalisation and the advent of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement (1995) reintroduced product patents and intensified international competition. Over time, India’s API manufacturing capacity declined in relative terms, with increasing import dependence on China—particularly for fermentation-based and antibiotic APIs [5].
Importance of Bulk Drug Production in Global Healthcare
Bulk drugs are the backbone of the pharmaceutical supply chain. APIs constitute 40–60% of the total cost of formulation manufacturing, making them economically and strategically crucial [6]. Global healthcare systems depend on the uninterrupted supply of affordable APIs for essential medicines, antibiotics, antivirals, and chronic disease treatments. India’s API manufacturing capacity not only supports its own formulation industry but also sustains the pharmaceutical sectors of over 200 countries that import Indian generics.
During the COVID-19 pandemic, India’s API dependency became a national concern. The temporary shutdown of Chinese plants in 2020 disrupted the supply of key antibiotics, vitamins, and anti-inflammatory APIs, exposing vulnerabilities in India’s pharmaceutical supply chain [7]. Despite this, India’s formulation exports surged due to its ability to produce finished drugs from limited stockpiles, demonstrating resilience but underscoring the urgent need for domestic API self-sufficiency. APIs are also essential for global public health programs: Indian-manufactured bulk drugs are key ingredients in antiretroviral (ARV) therapies, vaccines, and antibiotics supplied to developing nations through the WHO and Global Fund programs [8].
Current Status of India’s Bulk Drug Industry
As of 2025, India ranks third globally in volume and fourteenth in value of pharmaceutical production [9]. It produces over 500 APIs across therapeutic categories, including anti-infectives, cardiovascular agents, central nervous system (CNS) drugs, and anti-diabetics [10]. The bulk drug sector accounts for approximately USD 20 billion in revenue, with exports contributing nearly 60% of the output [11]. India’s leading API clusters—Hyderabad, Ankleshwar, Vadodara, and Baddi—house hundreds of production units, ranging from multinational firms to small and medium enterprises (SMEs). Despite this impressive scale, India imports 60–70% of its bulk drug intermediates and key starting materials (KSMs) from China [12].
To address this structural dependency, the Government of India launched major initiatives under the “Atmanirbhar Bharat” (Self-Reliant India) campaign. Notably, the Production Linked Incentive (PLI) Scheme for Bulk Drugs (2020) provides ?6,940 crore in incentives to boost domestic manufacturing of critical APIs, while the Bulk Drug Parks Scheme establishes integrated industrial zones with common infrastructure to reduce production costs [13]. Early outcomes show promising investments in fermentation-based antibiotics and vitamins, historically dominated by China. The Central Drugs Standard Control Organisation (CDSCO) regulates API production under the Drugs and Cosmetics Act (1940), enforcing Good Manufacturing Practices (GMP) to ensure quality and safety [14]. India’s reputation as a low-cost yet high-quality API producer has made it a preferred global supplier. However, maintaining this position requires tackling environmental compliance, enhancing R&D capacity, and adopting advanced technologies like continuous manufacturing, biocatalysis, and artificial intelligence (AI)-driven process optimisation [15].
Objectives and Scope of the Review
This review aims to provide a comprehensive analysis of bulk drug production in India, tracing its historical development, policy framework, technological advancements, and current challenges. It synthesises academic research, policy documents, and industry data to assess the sector’s readiness for future global competitiveness. The objectives include:
Significance of the Study
The significance of studying bulk drug production lies in its intersection between industrial policy, healthcare security, and international trade. APIs are not merely industrial commodities; they are critical to public health sovereignty. India’s pharmaceutical self-reliance depends on the robustness of its API ecosystem. Understanding the evolution, challenges, and future direction of this sector is therefore vital for policymakers, researchers, and industry leaders seeking to balance economic competitiveness with healthcare accessibility.
This review also contributes to the broader discourse on pharmaceutical globalisation, wherein India’s role is shifting from a generic formulation hub to an integrated innovation-driven manufacturing ecosystem. As global supply chains evolve post-pandemic, India’s strategic positioning in API manufacturing could redefine its role in ensuring affordable and sustainable healthcare worldwide.
Overview of Bulk Drug Production in India
Definition and Classification of Bulk Drugs
Bulk drugs, also known as Active Pharmaceutical Ingredients (APIs), are the biologically active chemical substances that produce the intended therapeutic effect in a pharmaceutical formulation. They form the essential core of every medicine—providing pharmacological activity, while excipients act as inert carriers or stabilisers [16]. According to the World Health Organization (WHO), an API is “a substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings” [17].
The U.S. Food and Drug Administration (FDA) defines APIs similarly, emphasising their central role in determining efficacy and safety [18]. In the Indian context, APIs are categorised as bulk drugs under the Drugs and Cosmetics Act (1940) and Rules (1945). The term “bulk drug” is used interchangeably with “drug substance,” distinguishing it from finished formulations like tablets, capsules, or injectables.
Classification of Bulk Drugs
Bulk drugs may be classified based on their origin, chemical structure, and method of production:
India produces over 500 APIs across major therapeutic classes, including antibiotics, antivirals, cardiovascular drugs, anti-diabetics, anti-inflammatory drugs, and oncology agents [19]. Among these, antibiotics and cardiovascular APIs dominate production volumes.
Key Players in the Indian Bulk Drug Industry
The Indian bulk drug industry is diverse, comprising large multinational corporations (MNCs), domestic pharmaceutical giants, and thousands of small and medium enterprises (SMEs).
Major Companies
Leading Indian API manufacturers include Dr Reddy’s Laboratories, Sun Pharmaceutical Industries, Aurobindo Pharma, Cipla, Lupin, Divi’s Laboratories, and Glenmark Life Sciences [20]. Divi’s Laboratories, for example, is among the world’s largest suppliers of generic APIs and custom synthesis intermediates. These large firms possess advanced R&D facilities, global regulatory certifications (US-FDA, EMA, WHO-GMP), and strong export networks.
SMEs and Cluster-Based Production
Approximately 3,000 firms and 10,500 manufacturing units are registered in India’s pharmaceutical sector, of which around 2,400–2,500 units are engaged in bulk drug production [21]. These are primarily concentrated in regional clusters such as:
SMEs form the backbone of India’s bulk drug ecosystem, particularly in generic APIs and intermediates. They contribute significantly to employment generation and local economic development but often face challenges in meeting global GMP standards and accessing affordable finance [22].
Government Agencies and Industry Associations
The Department of Pharmaceuticals (DoP) under the Ministry of Chemicals and Fertilisers is the nodal agency overseeing policy formulation for the pharmaceutical sector. Regulatory oversight is provided by the Central Drugs Standard Control Organisation (CDSCO), which operates through zonal and state drug control offices. Other relevant bodies include:
These institutions play key roles in ensuring regulatory compliance, export promotion, and skill development.
Production Processes and Technologies
Traditional Manufacturing Methods
Bulk drug manufacturing involves complex multi-step processes that vary by chemical nature and synthesis route. The major production routes are:
Chemical Synthesis: Traditional method using chemical reactions and catalysts to convert raw materials into APIs (e.g., acetylation for paracetamol).
Fermentation: A Biotechnological process employing microorganisms to produce antibiotics, vitamins, or amino acids [23].
Biotransformation and Extraction: Used for plant- or animal-derived products.
Each method involves several stages—reaction, purification, crystallisation, drying, milling, and packaging. Waste streams and effluents from these processes often contain hazardous residues, necessitating strict environmental controls.
Technological Advancements
In recent years, technological modernisation has reshaped API production in India.
India’s API producers are increasingly integrating Industry 4.0 technologies—IoT, automation, and data analytics—to improve compliance with international standards like ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients).
Quality Control and Regulatory Compliance
Quality assurance in bulk drug manufacturing is critical for maintaining international trust. Indian firms exporting to regulated markets (US, EU, Japan) must comply with Good Manufacturing Practices (GMP), ICH Q10 (pharmaceutical quality system), and ISO 9001 standards [27]. The CDSCO and state drug controllers conduct inspections to ensure adherence to these norms.
Analytical testing involves High-Performance Liquid Chromatography (HPLC), Infrared (IR), and Mass Spectrometry (MS) to confirm purity, identity, and potency of APIs [28]. India has also adopted Quality by Design (QbD) and Process Analytical Technology (PAT) frameworks to improve control over variability and reproducibility during production [29].
Industrial Clusters and Infrastructure
India’s bulk drug production is supported by industrial clusters and pharma parks, which provide shared utilities like effluent treatment plants (ETPs), solvent recovery units, and energy-efficient boilers. The Bulk Drug Parks Scheme (2020) facilitates infrastructure development through financial assistance of up to ?1,000 crore per park [30]. These parks aim to reduce the cost of production by 15–20% and promote sustainable industrial practices.
R&D-Driven Production Transformation
Research-driven manufacturing, supported by institutions like NIPERs and CSIR laboratories, has promoted indigenous process development and scale-up capabilities. Several Indian API producers are now shifting from generic chemical synthesis to high-value
APIs, such as oncology and complex injectables. Collaborative initiatives with universities and startups are also fostering innovation in biocatalytic routes, nanotechnology-enabled APIs, and green chemistry [31].
Indian Regulatory Bodies and Their Roles
The Indian pharmaceutical regulatory system has evolved significantly over the past five decades, establishing one of the most comprehensive frameworks in the developing world. Regulation of bulk drugs and APIs falls primarily under the Drugs and Cosmetics Act (1940) and the Drugs and Cosmetics Rules (1945), which collectively define standards for manufacturing, import, distribution, and sale of pharmaceuticals.
Central Drugs Standard Control Organisation (CDSCO)
The apex regulatory authority for pharmaceuticals in India is the Central Drugs Standard Control Organisation (CDSCO), operating under the Directorate General of Health Services, Ministry of Health and Family Welfare. Headed by the Drugs Controller General of India (DCGI), the CDSCO is responsible for:
The CDSCO’s regional offices are located in Mumbai, Kolkata, Chennai, and Ghaziabad, with zonal and sub-zonal laboratories providing analytical support. For APIs, the Central Drugs Laboratory (CDL) in Kolkata and the Indian Pharmacopoeia Commission (IPC) in Ghaziabad maintain national quality standards.
State-Level Regulatory Authorities
India’s federal structure delegates concurrent regulatory powers to state governments. State Drug Control Administrations (SDCAs) grant manufacturing licenses for bulk drugs, enforce quality standards, and inspect facilities under their jurisdiction [33]. The collaboration between CDSCO and SDCAs ensures dual-layered quality oversight—central approval for new APIs and state enforcement for operational compliance.
Other Regulatory and Advisory Bodies
These agencies collectively form a multi-tiered regulatory structure ensuring that India’s bulk drug industry aligns with international safety, quality, and environmental standards.
Key Regulations Governing Bulk Drug Production
Drugs and Cosmetics Act and Rules
The Drugs and Cosmetics Act, 1940, provides the legal foundation for regulating drug manufacture, import, and distribution. It defines “drug” to include bulk drug substances and empowers the government to establish standards for their identity, purity, and strength [35]. The Drugs and Cosmetics Rules, 1945, prescribe detailed manufacturing practices, quality assurance mechanisms, and penalties for non-compliance.
Notably, Schedule M of the Rules specifies Good Manufacturing Practices (GMP) for pharmaceuticals, covering aspects like premises, equipment, documentation, validation, and self-inspection [36].
To align with international standards, India adopted elements of ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients) and WHO-GMP guidelines, which define best practices for ensuring product consistency, purity, and traceability [37].
Good Manufacturing Practices (GMP) and Quality by Design (QbD)
Quality assurance is a non-negotiable component of API production. GMP requires every API manufacturer to establish a validated production process and maintain rigorous documentation for traceability. The Quality by Design (QbD) approach introduced by the
CDSCO encourages scientific risk-based process control and analytical technology integration [38].
The QbD framework involves identifying Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) that influence product quality. Manufacturers must demonstrate robust control strategies and statistical validation to minimise batch variability. Major Indian producers such as Sun Pharma, Lupin, and Dr Reddy’s have integrated QbD in their R&D workflows to meet the stringent requirements of US-FDA and EMA audits [39].
Environmental Regulations for Pharmaceutical Manufacturing
Bulk drug production is highly resource-intensive, often generating solvent-heavy effluents and antibiotic residues that contribute to antimicrobial resistance (AMR). The Central Pollution Control Board (CPCB) and State Pollution Control Boards (SPCBs) regulate environmental compliance under the Water (Prevention and Control of Pollution) Act, 1974 and the Air (Prevention and Control of Pollution) Act, 1981 [40].
Pharmaceutical units are mandated to operate Effluent Treatment Plants (ETPs) and adopt Zero Liquid Discharge (ZLD) technologies. Additionally, the Pharmaceutical Industry Standards for Effluent Emission (2019) set by the CPCB specify permissible limits for Total Dissolved Solids (TDS), Chemical Oxygen Demand (COD), and biological contaminants [41]. Failure to comply can result in suspension of manufacturing licenses.
Environmental audits are increasingly being tied to ESG (Environmental, Social, and Governance) performance metrics, influencing investment attractiveness and export eligibility.
Government Initiatives and Policies
Make in India Initiative
Launched in 2014, Make in India is the flagship industrial program aimed at transforming India into a global manufacturing hub. The pharmaceutical sector was identified as a key priority area, emphasising self-reliance in bulk drug production [42]. The initiative encourages both domestic and foreign investment in pharmaceutical manufacturing through fiscal incentives, simplified regulatory approvals, and infrastructure support.
Under this framework, the government promoted the development of Pharma Clusters and Special Economic Zones (SEZs) dedicated to bulk drug and formulation production, such as those in Gujarat, Telangana, and Andhra Pradesh.
Production Linked Incentive (PLI) Scheme
One of the most transformative interventions in recent years, the Production Linked Incentive (PLI) Scheme for Bulk Drugs (2020), allocates ?6,940 crore (≈USD 940 million) to support domestic manufacturing of 41 critical APIs, Key Starting Materials (KSMs), and Drug Intermediates (DIs) [43]. The scheme provides 5–20% financial incentives on incremental sales over six years.
Implementation is overseen by the Department of Pharmaceuticals (DoP). The first round of approved projects includes production of key fermentation-based APIs like penicillin-G, erythromycin, and vitamin B12, along with synthetic molecules such as paracetamol and ibuprofen [44]. Early indicators suggest that the PLI scheme will reduce import dependence on China from 70% to below 40% by 2026 [45].
Bulk Drug Parks Scheme
Complementing the PLI program, the Bulk Drug Parks Scheme (2020) supports the creation of three mega parks in Himachal Pradesh, Gujarat, and Andhra Pradesh, each with a financial outlay of ?1,000 crore. These parks offer shared infrastructure such as Common Effluent Treatment Plants (CETPs), solvent recovery systems, power supply, and logistics support [46]. The model aims to lower manufacturing costs, enhance sustainability, and attract investment from SMEs.
Other Relevant Policies
Policy Impact Assessment
Government interventions like the PLI and Bulk Drug Parks Schemes represent a paradigm shift from dependency-based growth to self-reliance-oriented industrial policy. Early estimates from the Department of Pharmaceuticals (2024) indicate that approved API projects under these schemes will generate investments worth ?17,000 crore, create over 20,000 direct jobs, and save approximately USD 3 billion annually in imports [50].
However, challenges persist. Bureaucratic delays in environmental clearances, the high cost of compliance, and infrastructural bottlenecks in smaller states hinder project execution. Experts argue for better coordination between the DoP, CDSCO, and CPCB to streamline approval timelines and facilitate integrated policy implementation [51].
The success of these initiatives will depend on fostering industry-academia partnerships, promoting R&D-driven manufacturing, and ensuring consistent policy continuity. The integration of green chemistry, digital process monitoring, and global regulatory harmonisation will determine whether India can regain its historic position as a global API powerhouse.
Current Market Size and Growth Trends
The Indian bulk-drug (API) sector represents a vital pillar of the national economy and a key contributor to the global supply chain. As of 2024–25, the Indian API market is valued at approximately USD 20 billion, growing at a compound annual growth rate (CAGR) of 8–10 % over the last five years [52]. Bulk-drug exports account for nearly 60 % of total production, demonstrating India’s strong outward orientation.
According to the Pharmaceuticals Export Promotion Council (Pharmexcil), India exported APIs worth USD 16.8 billion in 2023–24, representing 20 % of the country’s total pharma exports [53]. India ranks third worldwide in volume of pharmaceutical production but only fourteenth in value, owing to its cost-competitive generics-driven product mix [54].
Domestic Market
Domestically, API demand is driven by formulation manufacturers that supply both branded generics and government health programmes. The domestic API market was estimated at USD 7.5 billion in 2023, expected to reach USD 10 billion by 2027 [55]. Therapeutic segments with the highest API consumption include anti-infectives (32 %), cardiovascular drugs (15 %), central nervous-system products (11 %), anti-diabetics (10 %) and anti-inflammatory drugs (9 %).
India’s internal consumption is expanding due to the National Health Mission, growing chronic-disease burden, and inclusion of more essential medicines under the National List of Essential Medicines (NLEM 2022) [56].
Export Market and Destinations
India exports APIs and intermediates to more than 200 countries, including the United States, United Kingdom, Germany, Italy, Japan, South Korea, Brazil and South Africa [57]. The United States alone accounts for about 30 % of Indian API exports, followed by the EU (25 %), Africa (18 %), and Latin America (10 %).
Export growth accelerated after Indian firms obtained approvals from stringent regulatory authorities such as the US-FDA and European Medicines Agency (EMA). India currently hosts over 600 US-FDA-approved manufacturing sites, the highest number outside the United States [58]. However, price competition and increasing compliance costs are gradually compressing margins, prompting a shift toward higher-value APIs such as oncology molecules and complex injectables [59].
Global Market Share and Competitiveness
Globally, the API market is dominated by China (35–40 % share) and India (around 20 %) [60]. While China retains cost advantages in fermentation-based and intermediate APIs, India leads in chemical-synthesis-based products and regulated-market exports. Post-COVID-19, multinational companies are pursuing a “China + 1” sourcing strategy to diversify supply chains—an opportunity that India is well-positioned to exploit [61].
Economic Contribution of the Bulk-Drug Industry
Employment Generation
The Indian pharmaceutical sector—including APIs and formulations—employs over 2.9 million people directly and an additional 4–5 million indirectly through supply chains, logistics and retail distribution [62]. Bulk-drug manufacturing contributes a major share of skilled technical jobs: process engineers, chemists, microbiologists and quality-assurance professionals. Clusters in Hyderabad, Ankleshwar, Vadodara, and Baddi serve as regional employment hubs supporting ancillary industries such as packaging, glassware, and transport [63].
Government investment in Bulk Drug Parks is projected to create 20,000 direct jobs and 80,000 indirect jobs by 2026 [64]. The sector’s labour intensity also aligns with India’s demographic advantage—offering opportunities for semi-skilled workers in industrial zones.
Foreign Exchange Earnings
Pharmaceutical exports contribute nearly 5 % of India’s total merchandise exports [65]. Within this, APIs constitute a growing component, with net foreign-exchange earnings exceeding USD 10 billion in 2024. India’s positive trade balance in pharmaceuticals offsets part of the import bill arising from crude oil and electronics.
Foreign-exchange inflows are further strengthened by contract manufacturing and custom synthesis services, where Indian firms produce intermediates or APIs for global innovator companies under long-term supply agreements [66]. Divi’s Laboratories, Dishman Carbogen Amcis, and Laurus Labs exemplify this model.
Contribution to GDP and Industrial Growth
The pharmaceutical industry contributes roughly 2 % of India’s GDP and 12–13 % of manufacturing GVA [67]. Bulk drug production itself represents about 35 % of total pharmaceutical output. According to the Reserve Bank of India (RBI), the gross value addition from pharmaceuticals rose from ? 1.8 trillion in 2017-18 to ? 3.1 trillion in 2023-24 [68].
The PLI and Bulk Drug Parks schemes are expected to increase this contribution by an additional 0.3 percentage points to GDP by 2026 [69]. Besides economic growth, the sector enhances India’s global technological profile through chemical-engineering expertise and innovation spill-overs into allied industries such as speciality chemicals and biotechnology.
Challenges and Opportunities
Dependence on China
A persistent structural weakness in India’s API economy is its dependence on Chinese imports for Key Starting Materials (KSMs) and intermediates. Presently, 70 % of India’s API imports—notably antibiotics, vitamins, and fermentation-based products—originate from China [70]. This dependence is rooted in China’s lower production costs, large-scale fermentation capacity, and aggressive government subsidies.
During the COVID-19 pandemic, the supply-chain disruption of APIs such as azithromycin, paracetamol, and vitamin C exposed India’s vulnerability [71]. Addressing this challenge requires domestic capacity expansion, diversification of import sources (e.g., South Korea, the EU), and accelerated implementation of the PLI scheme.
Pricing Pressures and Profit Margins
While India enjoys cost advantages, intense global competition and price controls constrain profitability. APIs face price erosion of 8–12 % annually in regulated markets due to tender-based procurement systems [72]. Moreover, the National Pharmaceutical Pricing Authority (NPPA) imposes ceiling prices on essential bulk drugs, which, while ensuring affordability, can discourage innovation investment. Firms are increasingly turning to high-margin custom-synthesis contracts and value-added complex APIs to sustain growth [73]
Regulatory and Quality Compliance
Compliance with international standards (US-FDA, EMA, PMDA) requires substantial investment in quality systems, analytical labs, and skilled manpower. SMEs often struggle to meet these expectations, leading to occasional import alerts or warning letters [74]. Strengthening regulatory capacity-building programmes through the National Institute of Pharmaceutical Education and Research (NIPER) network is essential for sustaining export credibility [75].
Environmental Challenges
Bulk-drug clusters—particularly in Hyderabad and Ankleshwar—face scrutiny for effluent discharge and antibiotic residues contributing to antimicrobial resistance (AMR) [76]. Compliance with Zero Liquid Discharge (ZLD) norms and investment in common effluent treatment plants (CETPs) increase operational costs. However, adherence to environmental standards is now a prerequisite for export certification under the EU’s Green Manufacturing Directive [77].
Opportunities for Expansion and Diversification
Despite these constraints, multiple growth opportunities exist:
Strategic Positioning in the Global Supply Chain
The realignment of global pharmaceutical supply chains post-pandemic presents India with an unprecedented window to emerge as a second manufacturing hub after China. Government-to-government collaborations—such as the India-EU Trade and Technology Council (TTC 2023) and the US INDO-PACIFIC Economic Framework (IPEF)—are exploring mutual recognition of quality standards and co-investment in API infrastructure [82]. The establishment of API Data Exchange Platforms under the PLI scheme will further enhance transparency and export readiness.
R&D Infrastructure in India
The strength of India’s bulk-drug sector rests not only on scale and cost competitiveness but increasingly on research and development (R&D) capabilities. A vibrant R&D ecosystem enables continuous process innovation, cost reduction, and compliance with international quality standards.
Government and Public Institutions
India’s public-sector research capacity is anchored in organisations such as the Council of Scientific and Industrial Research (CSIR), which operates laboratories including the Indian Institute of Chemical Technology (IICT, Hyderabad) and the National Chemical Laboratory (NCL, Pune). These institutes have developed numerous synthetic routes for APIs such as ciprofloxacin, diclofenac, and atorvastatin [83].
The Department of Pharmaceuticals (DoP) funds seven National Institutes of Pharmaceutical Education and Research (NIPERs) that provide postgraduate training and undertake applied research in API synthesis, process intensification, and quality assurance [84]. Collaboration between CSIR labs, NIPERs, and industry has accelerated technology transfer and scale-up activities.
Other agencies, such as the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology (DBT), support biopharmaceutical and enzyme-engineering projects relevant to fermentation-based APIs [85]. These public programs provide the foundation for innovation-driven manufacturing.
Private Sector and Industry R&D
Leading Indian pharmaceutical companies—Dr Reddy’s Laboratories, Sun Pharma, Lupin, Aurobindo Pharma, and Divi’s Laboratories—invest between 6 % and 9 % of their revenues in R&D [86]. Their research focuses primarily on:
Indian firms increasingly collaborate with multinational pharmaceutical innovators through Contract Research and Manufacturing Services (CRAMS) and Custom Synthesis arrangements. This model not only diversifies income streams but also transfers know-how in advanced analytical techniques and regulatory science [87].
Academic Collaborations
Universities and technical institutes—IITs, ICT Mumbai, BITS Pilani, Jadavpur University, and others—serve as key partners in developing new reaction pathways and catalysts. Sponsored research projects through SERB (Science and Engineering Research Board) and UGC-Industry Interaction Cells are producing significant intellectual property (IP) in chiral synthesis and continuous-flow systems [88].
Ennovation in Bulk-Drug Synthesis
Novel Synthetic Routes and Green Chemistry
Modern bulk-drug synthesis in India is shifting toward sustainable chemistry. Innovations include solvent-free reactions, aqueous-phase catalysis, and the use of ionic liquids to minimise environmental footprint [89]. Indian API manufacturers such as Laurus Labs and Jubilant Ingrevia employ enzyme-catalysed reactions for high-purity intermediate production.
The Green Chemistry Network Centre (GCNC) at the University of Delhi promotes the adoption of eco-friendly synthesis across the industry. Implementation of the 12 Principles of Green Chemistry has reduced solvent consumption by 20 – 30 % in selected API plants [90].
Process Optimisation and Cost Reduction
Continuous improvement in yield and process efficiency is a hallmark of India’s competitive API production. Techniques include:
These innovations not only cut production costs but also strengthen regulatory compliance through reproducible, validated manufacturing processes.
Development of New Drug Delivery Systems
Though API manufacturers primarily target raw-material supply, several Indian firms are expanding vertically into drug-delivery research. Efforts include nano-API formulations, lipid nanoparticles, and sustained-release technologies that enhance bioavailability [92]. Integration of delivery-system design with bulk-drug synthesis shortens product-development cycles and expands export potential for finished formulations.
Emerging Trends in Bulk-Drug Research
Biocatalysis and Enzyme Engineering
Biocatalysis employs enzymes or whole-cell systems to catalyse chemical reactions under mild conditions. India’s fermentation expertise and biotech talent pool position it favourably for large-scale biocatalytic API manufacture. Institutes such as CSIR-NIIST (Thiruvananthapuram) and NCL Pune have engineered transaminases and oxidoreductases for enantioselective synthesis of chiral intermediates [93]. Companies like Biocon Ltd. and Syngene International deploy recombinant E. coli and yeast systems for insulin analogues and biopharmaceutical APIs. Enzyme engineering reduces reaction steps, enhances yield, and aligns with green-chemistry objectives.
Continuous-Flow Chemistry
Continuous-flow manufacturing enables seamless production of APIs with improved safety and energy efficiency compared to batch processes. By controlling residence time and mixing parameters precisely, firms achieve consistent quality and lower waste generation [94].
Lupin Pharma has piloted continuous-flow plants for cardiovascular APIs like amlodipine, while Dr Reddy’s is integrating modular reactors for process intensification. Government agencies such as the Technology Development Board (TDB) and CSIR offer co-funding for flow-reactor research.
Artificial Intelligence (AI) and Machine Learning (ML)
The application of AI in API research is gaining momentum. Machine-learning algorithms predict reaction outcomes, select optimal solvents, and identify failure modes in synthetic routes [95]. AI-driven platforms such as Chemistry42 and DeepChem are being adopted by Indian firms for retrosynthetic analysis and process optimisation.
AI also enhances quality assurance through predictive maintenance of equipment and automated data integrity checks under GMP frameworks. These digital transformations align with the government’s vision of “Pharma 4.0”, where IoT and AI integrate with manufacturing for real-time decision making [96].
Collaborative Innovation and Open Science
Global health challenges such as antimicrobial resistance (AMR) and pandemic preparedness have triggered new collaborative models. Indian researchers participate in consortia like the Open Source Pharma Foundation (OSPF) and the Drugs for Neglected Diseases Initiative (DNDi) to develop affordable API routes for public-health priorities [97]. These platforms encourage data sharing and reduce duplication of effort in early-stage process development.
Funding Mechanisms for Pharmaceutical R&D Sustained innovation requires consistent financing. R&D in India’s bulk-drug sector is supported through multiple channels:
Future Outlook
India’s roadmap for API self-reliance and global leadership by 2030 appears realistic, provided that policy execution and innovation investments continue consistently. Key priorities for the next decade include:
India’s comparative advantage lies in its blend of chemical expertise, cost efficiency, and an expanding domestic market. To fully capitalise on this advantage, the sector must transition from being a volume-driven supplier to a value-driven innovator, integrating sustainability, digitalisation, and inclusive growth.
If the current policy momentum continues and industry aligns with emerging technologies, India could evolve into a globally dominant, environmentally responsible API hub by 2030. The success of this transformation will not only secure national pharmaceutical sovereignty but also reaffirm India’s commitment to providing accessible, affordable, and high-quality medicines to the global community.
Final Reflection
The story of India’s bulk-drug production is one of resilience, reform, and reinvention. From the early vision of self-reliance in the 1970s to the present pursuit of innovation-driven sustainability, the sector mirrors India’s broader development journey. The path ahead demands synergy—between government policies, industrial discipline, academic innovation, and environmental stewardship.
In essence, bulk-drug production is not just an economic activity—it is a strategic imperative for healthcare security and global equity. With continued innovation, responsible regulation, and sustainability leadership, India’s pharmaceutical industry is poised to redefine the future of affordable healthcare worldwide.
REFERENCES
Raj Patil, Gauri Bhamare, Bhagyashree Koli, Swapnil Pradhan, Neha Patil, Kalyani Patil, Bulk Drug Production in India: Evolution, Challenges, and Future Prospects, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 3874-3891, https://doi.org/10.5281/zenodo.20226448
10.5281/zenodo.20226448
